Adoption and practice variation of DPYD genotyping prior to fluoropyrimidine therapy at two Canadian cancer centres.
528 Background: Fluoropyrimidines are widely used in the treatment of solid malignancies. Variants in the dihydropyrimidine dehydrogenase ( DPYD ) gene increase the risk of severe fluoropyrimidine-associated toxicity. Following guidance from Ontario Health (Cancer Care Ontario) recommending DPYD genotyping...